What drew you to pursue a career in oncology and what is it that inspires you most about working in this field?

Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?

The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...

Of late, pharmaceutical behemoth Pfizer Inc.’s PFE stock has struggled, but it remains a bargain with generous dividends. Its ...

For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X. About Pfizer Oncology At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our ...

Pfizer has announced plans to sell its remaining stake in Haleon plc, divesting approximately 662 million shares.

Biotech company Immunai, which developed an AI-based immune system mapping technology for drug development, announces the ...

The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

Disitamab vedotin, an antibody-drug conjugate (ADC), targets HER2-expressing cancer cells. It works by binding to HER2, being ...

Arvinas & Pfizer announce positive topline results from phase 3 VERITAC-2 clinical trial: New Haven, Connecticut Wednesday, March 12, 2025, 10:00 Hrs [IST] Arvinas, Inc., a clinic ...